Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab phase III trial in acquired thrombotic thrombocytopenic purpura
NL-OMON43776Phase 3Active, not recruiting
- Sponsor
- Ablynx
- Start
- Jan 2017
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of caplacizumab, sponsored by Ablynx. Started Jan 2017; status: active, not recruiting.
02
Drugs
caplacizumab
Beyond the preview
Go deeper on NL-OMON43776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43776.